Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(18 sites)
United States
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California Northwestern Memorial Hospital, Chicago, Illinois Massachusetts General Hospital Cancer Center, Boston, Massachusetts Beth Israel Deaconess Medical Center, Boston, Massachusetts Dana-Farber Cancer Institute, Boston, Massachusetts Stephenson Cancer Center, Oklahoma City, Oklahoma University of Pennsylvania, Philadelphia, Pennsylvania Vanderbilt-Ingram Cancer Center, Nashville, Tennessee Virginia Cancer Specialists, PC, Fairfax, Virginia Spain
NEXT Oncology - Hospital Quironsalud Barcelona - PPDS, Barcelona START Barcelona HM Nou Delfos, Barcelona Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON, Barcelona Hospital Clinico San Carlos, Madrid START MADRID Hospital Universitario Fundacion Jimenez Diaz - EDOS, Madrid START MADRID Hospital Universitario HM Sanchinarro - CIOCC, Madrid Clinica Universidad de Navarra, Pamplona NEXT Oncology - Hospital Quironsalud Madrid - PPDS, Pozuelo de Alarcón Hospital Clinico Universitario de Valencia, Valencia